Results of longitudinal analyses comparing SIGLEC1 and CK with disease activity scores (CMAS/PGA) for (A) 12 juvenile and (B) 14 adult dermatomyositis patients
| A: Patients with juvenile dermatomyositis | ||
| Do SIGLEC1/CK correlate with CMAS over time? | ||
| CMAS—all values* | n=65 betaST=−0.70; p<0.001 95% CI −0.85 to −0.54 | n=87 betaST=−0.39; p<0.001 95% CI −0.57 to −0.21 |
| CMAS—visits with complete data (SIGLEC1 and CK)† | n=53 betaST=−0.65; p<0.001 95% CI −0.80 to −0.49 | n=53 betaST=−0.50; p<0.001 95% CI −0.66 to −0.33 |
| Is the change of SIGLEC1/CK associated with a change in CMAS? Change between visits (∆ Visitt-1 and visitt): | ||
| CMAS—all values* | n=28 betaST=−0.53; p<0.001 95% CI −0.77 to −0.29 | n=41 betaST=−0.27; p=0.051 95% CI −0.62 to –0.08 |
| CMAS—visits with complete data (SIGLEC1 and CK)† | n=16 betaST=−0.42; p<0.001 95% CI −0.71 to −0.14 | n=16 betaST=−0.14; p=0.566 95% CI −0.39 to 0.11 |
| B: Patients with adult dermatomyositis | ||
| Do SIGLEC1/CK correlate with PGA over time? | ||
| PGA—all values* | n=45 betaST=0.54; p<0.001 95% CI 0.34 to 0.74 | n=41 betaST=0.17; p=0.149 95% CI −0.11 to 0.45 |
| PGA—visits with complete data (SIGLEC1 and CK)† | n=41 betaST=0.52; p<0.001 95% CI 0.32 to 0.72 | n=41 betaST=0.17; p=0.149 95% CI −0.11 to 0.45 |
| Is the change of SIGLEC1/CK associated with a change in PGA? Change between visits (∆ visitt-1 and visitt): | ||
| PGA—all values* | n=31 betaST=0.48; p=0.003 95% CI 0.16 to 0.79 | n=25 betaST=−0.10; p=0.634 95% CI −0.45 to 0.27 |
| PGA—visits with complete data (SIGLEC1 and CK)† | n=25 betaST=0.60; p=0.001 95% CI 0.29 to 0.91 | n=25 betaST=−0.10; p=0.634 95% CI −0.45 to 0.27 |
Statistical analysis was performed using a two-level mixed-effects linear regression model.
*SIGLEC1 and CK values were analysed independently of each other.
†Included only those visits where both biomarkers (SIGLEC1 and CK) were assessed (complete-case analysis).
betaST, standardised beta coefficient; CK, creatine kinase; CMAS, Childhood Myositis Assessment Scale; n, number of analysed values; PGA, Physician Global Assessment; SIGLEC1, sialic acid binding Ig-like lectin 1.